跳至主要内容
临床试验/NCT04604197
NCT04604197进行中(未招募)不适用

ANGiographic Evaluation of Left Main Coronary Artery INtErvention

Fundación EPIC30 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2021年4月16日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
400
试验地点
30
主要终点
Composite endpoint: defined as : death, myocardial infarction, and stroke.

研究概览

简要总结

To assess if an angiographic follow-up at 6 months after Percutaneous Coronary Intervention in Left Main Coronary Artery Disease decrease the composite objective of death, myocardial infarction, and stroke at 36 months.

详细描述

Percutaneous coronary intervention (PCI) with drug-eluting stents in left main (LM) disease has demonstrated similar results than surgical revascularization in patients with SYNTAX score < 33, being the main drawback of PCI a higher rate of new revascularization. A small study found a reduction in the composite end-point of cardiac death, myocardial infarction and urgent revascularization with a routine angiographic follow-up. The investigators have designed a prospective, randomized, controlled, two-arm multicenter study in patients aged 18-85 with LM disease and SYNTAX score <33 and in cases ≥ 33 based on the Heart Team decision to assess the benefit of a routine angiographic follow-up 6 months after LM stenting. After the index procedure and before hospital discharge the patient will be randomized to routine invasive angiographic follow-up at 6 months plus clinical follow-up at 6 months, 1, 2 and 3 years vs. the control arm, which would be followed clinically at 6 months, 1, 2 and 3 years. Based on our calculations, an adequately powered trial would require 1009 patients per arm but due to the uncertainty of the results and the current economical restrictions we have designed a pilot study in 400 patients to find out the convenience of an adequately powered trial. All the lesions should be treated with an everolimus eluting stent with permanent fluoropolymer. It will be desirable to achieve complete revascularization and it will be highly recommended to perform the procedures guided with an intravascular image technique (OCT or IVUS (IntraVascular UltraSound) according to operator´s criteria). The main outcome will be death, myocardial infarction and cerebrovascular accident at 3 years. The initial percutaneous technique and the decision about the convenience and way of revascularization in case of restenosis in the follow-up will be left at the operator´s discretion, according in the most adequate way to the current guidelines. Nonetheless, the investigators are strongly encouraged to rely on intravascular techniques, based on either imaging or physiology. In those cases with in-stent hyperplasia with doubts about possible restenosis, FFR and RFR (Resting full-cycle ratio) will be performed, with low threshold to achieve a high rate of ruling out the restenosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age: 18- 85 years at the date of the PCI.
  • With PCI for presenting de novo lesions in the Left Main Artery by implanting a cobalt-chrome stent with everolimus-eluting fluoropolymer.
  • Informed consent signed.

排除标准

  • Refusal to participate in the study.
  • Patients with left main disease who have been admitted with STEMI and have undergone primary angioplasty in a culprit lesion different than the left main. The left main lesion has been treated as a stage procedure and discharged with left ventricular ejection fraction < 35 %.
  • Previous coronary surgery.
  • Creatinine clearance <40 ml / min.
  • Contraindication for double antiaggregation after PCI.
  • Patients life expectancy <36 months.
  • Included in other studies or clinical trials.
  • Pregnant or lactating women.

研究组 & 干预措施

Angiography and Clinical Follow up

Experimental

After PCI. The patient is randomized to an angiographic follow-up at 6 months and a Clinical Follow to 36 months

干预措施: Angiography and Clinical Follow up (Other)

Clinical Follow up

Active Comparator

After PCI. The patient is randomized to a Clinical Follow to 36 months

干预措施: Clinical Follow up (Other)

结局指标

主要结局

Composite endpoint: defined as : death, myocardial infarction, and stroke.

时间窗: 36 months

Composite endpoint: defined as : death, myocardial infarction, and stroke.

次要结局

  • All Death(36 months)
  • Cardiac Death(36 months)
  • Target Vessel revascularization.(36 months)
  • Myocardial Infarction(36 months)
  • Stroke(36 months)
  • Stent thrombosis (ARC definite/probable)(36 months)
  • Major bleeding event (BARC type 2-5)(36 months)
  • Revascularization by CABG ( Coronary Artery Bypass Grafting) or PCI (Percutaneous Coronary Intervention)(36 months)

研究者

发起方
Fundación EPIC
申办方类型
Other
责任方
Sponsor

研究点 (30)

Loading locations...

相似试验